CAJ | 학술논문

目的：探讨吡格列酮对不稳定型心绞痛（UAP）合并2型糖尿病患者内皮祖细胞（EPCs）数量及脂联素水平的影响。方法入选自2010年6月至2011年5月在湖北医药学院附属太和医院住院的有UAP合并2型糖尿病患者57例，随机分为吡格列酮组（n=28）和对照组（n=29），吡格列酮组应用吡格列酮（30 mg/d）治疗，对照组患者不使用噻唑烷二酮类药物。治疗前及治疗12周时通过流式细胞技术双色分析法检测所有患者外周血中EPCs占有核细胞的百分比，其中EPCs用CD34+/KDR+双标记定位，比较两组患者在干预前后内皮祖细胞数量的变化及血清脂联素水平的变化。结果两组患者在治疗前EPCs的数量无统计学差异（P＞0.05）。治疗12周时，吡格列酮组患者EPCs数量较治疗前明显增加（0.023±0.010 vs.0.051±0.012，P＜0.01）；对照组患者EPCs数量在治疗前后无统计学差异（P＞0.05）；12周时，吡格列酮组患者EPCs数量高于对照组患者（P＜0.028）。吡格列酮组血清脂联素水平在治疗前、后有统计学差异（P＜0.05）；对照组患者血脂联素水平在治疗前、后无统计学差异（P＞0.05）；12周时，吡格列酮组患者血清脂联素水平高于对照组患者（P＜0.05）。结论吡格列酮能够促进冠心病合并糖尿病患者EPCs的动员，提高患者血清脂联素水平。
목적：탐토필격렬동대불은정형심교통（UAP）합병2형당뇨병환자내피조세포（EPCs）수량급지련소수평적영향。방법입선자2010년6월지2011년5월재호북의약학원부속태화의원주원적유UAP합병2형당뇨병환자57례，수궤분위필격렬동조（n=28）화대조조（n=29），필격렬동조응용필격렬동（30 mg/d）치료，대조조환자불사용새서완이동류약물。치료전급치료12주시통과류식세포기술쌍색분석법검측소유환자외주혈중EPCs점유핵세포적백분비，기중EPCs용CD34+/KDR+쌍표기정위，비교량조환자재간예전후내피조세포수량적변화급혈청지련소수평적변화。결과량조환자재치료전EPCs적수량무통계학차이（P＞0.05）。치료12주시，필격렬동조환자EPCs수량교치료전명현증가（0.023±0.010 vs.0.051±0.012，P＜0.01）；대조조환자EPCs수량재치료전후무통계학차이（P＞0.05）；12주시，필격렬동조환자EPCs수량고우대조조환자（P＜0.028）。필격렬동조혈청지련소수평재치료전、후유통계학차이（P＜0.05）；대조조환자혈지련소수평재치료전、후무통계학차이（P＞0.05）；12주시，필격렬동조환자혈청지련소수평고우대조조환자（P＜0.05）。결론필격렬동능구촉진관심병합병당뇨병환자EPCs적동원，제고환자혈청지련소수평。
Objective To investigate the influences of pioglitazone on quantity of endothelial progenitor cells (EPCs) and adiponectin level in patients with unstable angina pectoris (UAP) complicating type 2 diabetes mellitus (T2DM). Methods The patients (n=57) were randomly divided into pioglitazone group (n=28) and control group (n=29), and pioglitazone group was treated with pioglitazone (30 mg/d) and control group was not given TZD drugs. The percentage of peripheral EPCs in karyocytes was detected by using flow cytometry and double color analysis before treatment and 12 w after treatment, and EPCs were localized with CD34+/KDR+double labeling. The changes of quantity of EPCs and level of serum adiponectin were compared between 2 groups before and after treatment. Results The quantity of EPCs had no statistical difference between 2 groups before treatment (P>0.05). After treatment for 12 w, the quantity of EPCs increased significantly in pioglitazone group (0.023±0.010 vs. 0.051 ±0.012, P<0.01), and had no statistical difference in control group (P>0.05). The quantity of EPCs was higher in pioglitazone group than that in control group 12 w after treatment (P<0.028). The level of serum adiponectin had statistical difference in pioglitazone group before and after treatment (P<0.05), while had no statistical difference in control group (P>0.05). The level of serum adiponectin was higher in pioglitazone group than that in control group 12 w after treatment (P<0.05). Conclusion Pioglitazone can improve the mobilization of EPCs and level of serum adiponectin in patients with UAP complicating T2DM.